Increasing survival of organ transplant patients by reducing time interval for transported organs

April 26, 2007

San Francisco, CA, April 26, 2007 - Preservation of an organ intended for transplant during transport from donor to recipient is of primary concern in ensuring a successful transplant. Research presented at the ISHLT 27th Annual Meeting and Scientific Sessions today explores two diverging systems for pump preservation - the Organ Care System (OCS) and the cold preservation method, and how they each effect survival for heart transplant patients.

The cold preservation method, which has been in practice for more than 25 years, delivers the organ in a non-functioning state immersed in a cold solution for preservation during transport. The time during transport in this method is referred to as cold ischemic time (CIT), more specifically the interval beginning when an organ is removed from the donor and is cooled with the solution, to the time when the organ is implanted.

Conversely, the Organ Care System (OCS) is based on warm blood perfusion technology, which it uses to maintain organs in a warm, functioning state. This state mimics the environment of the human body during transport from organ donor to recipient. Nutrient rich, oxygenated blood is continuously pumped through the heart in order to maintain the organ in a living, beating, state. Preserving an organ with this method reduces CIT and allows for evaluation of organ function during transport.

New data presented during a late afternoon session on Wednesday, Concurrent Session 2 Cardiac Ischemic Time: Warm, Cold, or Pump?, highlighted the benefits of reducing or eliminating CIT, such as increased availability of donor organs, improved transplant outcomes, and reduced costs associated with end stage organ failure. Presentations during the session outlined research results demonstrating that reducing CIT will increase survivorship, and further how the OCS may eliminate CIT almost entirely.

Gero Tenderich, M.D., Clinic for Thoracic and Cardiovascular Medicine, Bad Oeynhausen, Germany, provided results from the PROTECT I clinical trial, Prospective Multi-Center European Trial To Evaluate the Safety and Performance of the Organ Care System for Heart Transplants, during the Wednesday session (Abstract 10). The PROTECT I trial, which was performed in Europe, studied the efficacy of the OCS in regards to survivorship. The results demonstrate the use of the OCS in maintaining and transporting donated hearts for transplant surgery. Results showed 100 percent survival of patients 30 days post surgery. Results also revealed that using the OCS allowed for patients to spend less time on the ventilator and experience a quicker recovery in the hospital. The ability of the OCS to assess organ function was also discussed. The trial sites participating in the PROTECT I study included the Clinic for Thoracic and Cardiovascular Medicine, Bad Oeynhausen and the German Heart Institute in Berlin, Germany, as well as Papworth Hospital and Harefield Hospitals, NHS Trusts in Cambridge and Middlesex, United Kingdom, respectively.

The U.S. Food and Drug Administration has recently granted IDE approval to initiate the pilot phase of the PROCEED multi-center clinical trial in the U.S. to evaluate the safety and performance of the OCS for heart transplants. The PROCEED trials will take place at five centers, including University of Pittsburgh Medical Center in Pittsburgh; Heart, Lung, and Esophageal Surgery Institute in Pittsburgh; UCLA Medical Center in Los Angeles; The Cleveland Clinic Heart and Vascular Institute in Cleveland, The University of Chicago Hospitals Cardiac Center in Chicago and Brigham & Women's Hospital in Boston.

"The PROTECT trial results establish validity of the Organ Care System. Given its relatively recent introduction to the transplant world, we are excited about the results and look forward to seeing what further tests will demonstrate about this innovative system," said Bruce Rosengard, M.D., Director of Cardiac Transplantation at Massachusetts General Hospital and former ISHLT board member.

Analysis of data from studies conducted in the United Kingdom and Australia were presented by Julian Gooi, M.D., Alfred Hospital, Melbourne, Australia, The Potential Impact of Reducing Cold Ischaemic Time on Cardiac Transplant Survival (Abstract 8) during the same Concurrent Session. The analysis concluded that a CIT of less than one hour would result in longer-term survival or an increase in life-years gained (LYG). Overall, the research showed that there were 2.2 LYG per donor heart for the United Kingdom transplant program, and 2.1 LYG per donor heart for the Australian transplant program. Dr. Gooi's presentation demonstrated how reworking the means of transport and developing central procurement and transplant centers could be beneficial to the transplant community.

"These results should alert the transplant community of issues that need immediate attention in order to increase survivorship in transplant patients. The amount of life years gained through better efficiency within the organ transport system is astonishing," continued Dr. Rosengard.
The PROTECT I trials were sponsored by TransMedics (Andover, MA).


The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. Created in 1981, the Society now includes more than 2,200 members from 45-plus countries, representing a variety of disciplines involved in the management and treatment of end-stage heart and lung disease.

ISHLT maintains two vital databases. The International Heart and Lung Transplant Registry is a one-of-a-kind registry that has been collecting data since 1983 from 223 hospitals from 18 countries. The ISHLT Mechanical Circulatory Device (MCSD) database has been collecting data since 2002 with the aim of identifying patient populations who may benefit from MCSD implantation; generating predictive models for outcomes; and assessing the mechanical and biological reliability of current and future devices. For more information, visit

International Society for Heart and Lung Transplantation

Related Clinical Trial Articles from Brightsurf:

Clinical trial investigates gabapentin for alcohol use disorder
This randomized clinical trial investigated if gabapentin, a drug often used to treat nerve pain, would be useful in the treatment of patients with alcohol use disorder (problem drinking that becomes severe) and a history of alcohol withdrawal symptoms.

Electrical stimulation helps treat constipation in clinical trial
Electrical stimulation benefited women with constipation in a recent clinical trial published in Alimentary Pharmacology & Therapeutics.

Treatment of migraine pain in randomized clinical trial
Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.

First entirely digital clinical trial encourages physical activity
As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study.

HIV vaccine nears clinical trial following new findings
A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.

Sickle cell drug showing promise in clinical trial
An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.

Meditation goes digital in new clinical trial
Scientists at UC San Francisco have developed a personalized digital meditation training program that significantly improved attention and memory in healthy young adults -- a group already at the peak of brain health -- in just six weeks.

Could blockchain ensure integrity of clinical trial data?
UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain.

Eating crickets can be good for your gut, according to new clinical trial
A new clinical trial shows that consuming crickets can help support the growth of beneficial gut bacteria and that eating crickets is not only safe at high doses but may also reduce inflammation in the body.

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy®).

Read More: Clinical Trial News and Clinical Trial Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to